ADCs combine targeted antibodies with cytotoxic agents and are designed to enable more selective delivery of therapies to tumor cells.However,the clinical utility of existing ADCs has been constrained by safety concerns,with payload-related toxicities continuing to limit dose increasing and thus overall therapeutic potential.

We have developed a proprietary RICIN ADC platform designed to address these challenges through an alternative design approach.Instead of relying on highly cytotoxic payloads,the platform utilizes engineered payloads that are intended to remain relatively inactive until delivered intracellularly via targeted antibodies.This approach is designed to enable selective tumor cell targeting while reducing payload related off-target effects,and to support improvements in pharmacokinetics,manufacturability and overall therapeutic window.

Our pipeline of ADC drug candidates currently includes AND025 and AND027,both developed using  the  RICIN  ADC  platform,demonstrating  its  potential  applicability  across  multiple  oncology indications.AND025 is being developed for AML and solid tumors,while the development of AND027 is focused on solid tumor indications,including those with resistance to existing ADC therapies.We are also expanding a broader set of engineered payloads to  support the continued development of this platform.